Part-Time or All-In? The Scientist Entrepreneur's Dilemma

Part-time or All-in? Beyond the difference in time commitment, scientists’ mindsets toward entrepreneurship also differ fundamentally.

Scientist-led startups have become a trend, with projects stemming from the commercialization of scientific research poised to elevate industry innovation to new heights. However, if you have been following the commercialization of scientific achievements for more than three months, you are likely to encounter two contrasting viewpoints: one camp argues that scientists should commit to entrepreneurship full-time, viewing this as a testament to their determination and attitude toward technology transfer; the other contends that scientists should not pursue entrepreneurship full-time, citing the substantial uncertainties involved—such as researchers’ limited market awareness and a disconnect between innovation directions and industrial needs—which all pose risks to the successful implementation of these achievements.

Part-time or All-in? This has seemingly become a nationwide debate in the field of scientific research translation and innovation. Do scientists need to “go all in” when starting businesses? Is it a disaster for scientists to sit at the negotiation table? Almost everyone has their own insights and opinions.

In this article, we will discuss this topic by analyzing the advantages and challenges of scientists engaging in part-time versus full-time entrepreneurship.

It must be acknowledged that for scientist-entrepreneurs, there is a fundamental difference in mindset between working part-time and full-time.

Part-time involvement means that scientist-entrepreneurs dedicate less time to the venture and play a smaller role within the team. Even if they choose to participate in the commercialization and implementation of their research outcomes, indicating a certain level of confidence in the technology’s market viability, their primary focus will remain on scientific research.

The advantage of this arrangement is that scientists can remain true to their roles, continuing to devote greater energy to scientific research, their area of expertise, while also balancing the needs of technology commercialization. For enterprises, this allows professionals to focus on their respective specialties; corporate management can operate in a market-oriented manner, thereby reducing anxiety stemming from scientists’ immature business thinking. On the other hand, scientists and their laboratory teams will continue to serve as a solid foundation for corporate R&D innovation and for building industry moats.

However, every coin has two sides. Scientists who embark on entrepreneurial ventures while maintaining their primary roles also face significant challenges. On one hand, they encounter skepticism from investors, who question whether their investments are sufficiently protected if the scientists cannot devote their full time and energy to the project. On the other hand, these scientists face considerable challenges in managing their personal time.

An individual’s energy is finite. Scientific research and the commercialization of research outcomes require fundamentally different mindsets. Although scientists who launch startups on a part-time basis may devote less time to their ventures, they remain the core decision-makers within the company. During the early stages of a startup, the scientist’s involvement may be required in matters ranging from overall strategic planning and fundraising to personnel recruitment. Undoubtedly, scientists often need to expend even more energy during this initial phase.

Ultimately, scientists become overwhelmed by the demands of commercializing their research outputs, disrupting their original work and personal lives, leading to severe internal burnout that leaves them unable to accomplish anything.

In contrast, the advantages of scientists embarking on full-time entrepreneurship are evident. The most intuitive benefit is that it allows entrepreneurs to perceive the scientist’s confidence and determination in commercializing their technology. First, the ability to commit to entrepreneurship full-time indicates that the scientist has sufficient motivation to translate their research outcomes into practical applications. This motivation may stem from confidence in the project and technology, or from a passion for transforming research findings into marketable products. Second, in terms of mindset, choosing to go “all in” signifies that the scientist is prepared to continuously embrace change, adjust their mentality, and truly transition into the role of an entrepreneur.

However, on the other hand, scientists often lack expertise in management, equity structures, and business negotiations. When scientists assume the role of corporate leaders, their enterprises face inherent risks.

In summary, both part-time and full-time entrepreneurship come with distinct advantages and challenges. So, are there corresponding strategies for different entrepreneurial states?

For scientist-entrepreneurs, the emphasis of their value varies at each stage of the company’s development.

Amid national policy support and capital-driven momentum, the commercialization of scientific research is experiencing its best opportunity in nearly two decades. Investors are gradually losing interest in service-oriented models and consumption-driven projects. Highly innovative concepts such as “global first-in-class” and “chokepoint technologies” have become buzzwords in the investment sector.

In this context, scientist-entrepreneurs hold a distinct advantage. Their long-term engagement with and participation in research and innovation at the technological frontier enable them to identify technical barriers within their field more rapidly and accurately. Once these barriers are overcome, they are well-positioned to capture the industry’s commanding heights.

Therefore, in the early stages, scientists play a decisive role within the team; they virtually embody breakthroughs and the practical implementation of cutting-edge technologies, serving as a near-direct representation of the company’s innovation level within the industry.

However, as scientific and technological achievements are translated into practical applications, the role of scientists will also evolve. During the mid-stage of commercialization, breakthroughs in frontier technologies have already been achieved, and R&D efforts in startups shift from technological research to product development. At this stage, product development places greater emphasis on engineering implementation compared to frontier technology exploration. In contrast to the divergent thinking style of scientists, engineers employ a more focused mindset. Therefore, the value of engineers becomes more pronounced during this phase.

Certainly, scientists continue to play a role in this process. Breakthroughs in underlying technologies and basic research may still be required to advance from principle prototypes to engineering prototypes; therefore, interaction and collaboration between scientists and engineers remain essential throughout this process.

Transformation continues to deepen. Once product refinement is complete, the company enters the phase of commercial implementation and market promotion. At this stage, the value of scientists becomes prominent once again. Although the product has matured, startups must continuously iterate and update their technologies to maintain a technological lead within the industry. Furthermore, for long-term development, a company typically requires more than one product pipeline. Therefore, after initial product commercialization, startups still need to embark on the next cycle from basic research to product implementation.

Moreover, bringing products to market requires extensive marketing and validation. Throughout this process, scientists are still needed to leverage their influence to support the marketing department. For instance, the downstream users of certain innovative products are themselves research institutions or hospital experts; similarly, for physician entrepreneurs whose products target hospitals, market penetration largely depends on the physicians’ personal influence within the industry.

For scientists pursuing entrepreneurship on a part-time basis, the roles and values vary across different stages, as do the time and energy investments. By understanding the priorities and key tasks at each stage, reasonable time management may enable these scientist-entrepreneurs to navigate their dual commitments with greater ease and proficiency.

For scientists who embark on full-time entrepreneurship, the primary risk stems from deficiencies in business acumen. In scientific research, a scientist may gain renown for excelling in a specific skill or a particular area of study. However, entrepreneurship tests an entrepreneur’s comprehensive competencies, and even a single weakness can lead to total failure.

So, how can risks be mitigated when scientists lack business acumen? A classic saying offers the answer: “If you cannot create a perfect individual, then build a perfect team.”

An analysis of the equity structures of scientific research commercialization projects reveals several commonalities. In addition to scientists, who serve as decision-makers holding core technologies and possess absolute controlling stakes, two other key roles are typically present in the structure: the CEO responsible for management and operations (i.e., the entrepreneurial partner discussed in our previous issue), and the engineer or product director overseeing product development.

In the early stages of a startup, the addition of a business co-founder can significantly compensate for scientist entrepreneurs’ deficiencies in business negotiations and corporate management. In the article “The Business Co-Founder,” we have provided a detailed overview of the value and distinctive characteristics of this role. Meanwhile, engineers and product directors equip the team with capabilities in product design and refinement. After all, most technologies ultimately enter the market in the form of products or services. Engineers and product directors thus play a critical role in digesting underlying technologies and facilitating their transformation into market-ready products.

In the process of translating scientific research into commercial applications, investors serve as both talent scouts and guides. The head of a leading venture capital firm’s technology transfer fund once revealed that while investment due diligence for Series A projects might previously have taken only dozens of hours, early-stage projects involving the commercialization of scientific achievements can require hundreds of hours combined for pre- and post-investment efforts. In some cases, despite substantial input, the company may remain in a state with no tangible outcomes, offering no clear path toward product development or exit through financing. Moreover, beyond capital, investors may need to provide intangible assets such as resources, networks, and expertise.

Despite differences in formal status, early investors in scientific and technological achievement commercialization projects effectively assume the responsibilities of co-founders, given the time and effort they invest. Another investor also revealed that their collaboration with scientists dates back to the pre-startup phase.

For example, when encountering a scientist whose work they find promising, some investors do not immediately encourage the scientist to establish a company. Instead, they leverage their own resources and networks to help the scientist conduct proof-of-concept assessments regarding the commercial viability of the technology and its market potential. For instance, investors may introduce the scientist to potential upstream and downstream clients. By gathering feedback from these players across the industry chain, the scientist can gain a clearer understanding of the industry landscape and develop a more informed strategy for industrialization. At this stage, the goal is to provide the scientist with the necessary conditions to carefully consider whether to embark on entrepreneurship. Only then do they discuss funding.

As translational projects progress, a company may require an increasingly diverse set of elements. These include teams for product commercialization, regulatory approval, and marketing; business development (BD) departments for pipeline management; or specialized technical secondary development teams focused on the “1–3” stages of research. In the early stages, when scientists lack sufficient experience, reliable partners and investors, along with a team capable of effectively executing their vision, can significantly reduce the risks associated with scientist-led startups.

Let’s return to the question of whether scientist-founders should pursue entrepreneurship part-time or go all in.

Having clarified the pros and cons of part-time versus full-time entrepreneurship, along with potential solutions, it is important to recognize that these are not mutually exclusive or permanent choices. For scientists engaged in part-time entrepreneurship, they may still choose to fully commit to their startups once certain milestones are achieved. Conversely, for those who have embarked on full-time entrepreneurship, there is still a safety net; most scientists retain the capital and credentials to return to academia or pursue other career opportunities.

Against this backdrop, the debate over “Part-time” versus “All-in” appears less contentious.

Let us delve deeper. Do all scientists aspire to become entrepreneurs? And do the achievements of scientists who lack such ambition hold no value for commercialization? I believe the answer to both questions is no. Furthermore, does the success of technology transfer depend entirely on whether scientists engage in full-time entrepreneurship? I think not.

Let us approach this issue with the end in mind. The prerequisite for translating scientific research achievements into practical applications is that these achievements possess commercialization value. Only under this premise should we discuss whether the inventors of the technology should embark on full-time entrepreneurship. Among these inventors, some are indeed sufficiently motivated and willing to shift their mindset to learn about commercial logic and management strategies; others are purely researchers who, compared to commercialization and entrepreneurship, prefer to devote their time to their familiar scientific research endeavors.

For the former, although they may encounter difficulties in the early stages, extensive experience, learning, and hands-on practice actually provide them with a favorable training environment. Coupled with their determination to transform, their metamorphosis from scientists into entrepreneurs may merely be a matter of time. As for the latter, if scientists lack the intention to start businesses, why dwell on this? Participating as scientific advisors through technology transfer or licensing is also a sound strategy. There are numerous successful cases both in China and abroad.

There is no definitive answer to whether scientists should pursue entrepreneurship on a full-time basis. A more feasible approach may be to tailor the strategy to the individual characteristics of each scientist. Therefore, rather than engaging in polarized debates over full-time commitment, it is more productive to objectively discuss which types of scientists are suited for full-time entrepreneurship and which are better suited for part-time involvement. After all, the core objective of translating research into commercial applications is to bring highly innovative scientific achievements into industry, not to turn every scientist into an entrepreneur.